Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Behind the Study: Retaining Nanomolar Potency in Lung Cancer

Oncotarget

August 16, 2021
Dr. Aditya Kulkarni discusses a study he co-authored, published by Oncotarget in 2021, and entitled, “The acylfulvene alkylating agent, LP-184, retains nanomolar potency in non-small cell lung cancer carrying otherwise therapy-refractory mutations.” continue reading »

Trending With Impact: Analysis of Breast Cancer in Nigerian Women

Oncotarget

August 12, 2021
In this trending paper published by Oncotarget in 2021, a cohort of Nigerian women were assessed for a useful biomarker in aggressive molecular subtypes of breast cancer. continue reading »

Epigenetic Signatures Differentiate Leiomyosarcoma Subtypes

Oncotarget

August 4, 2021
In the cover paper chosen for Oncotarget’s Volume 12, Issue 16, researchers from Yale University made headway in stratifying subtypes of a rare and aggressive form of cancer: leiomyosarcoma (LMS). continue reading »

Table of Contents: Oncotarget’s Volume 12, Issue #16

Oncotarget

August 3, 2021
Read short summaries of the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 16. continue reading »

Biomarker Predicts Treatment Efficacy in Triple-Negative Breast Cancer

Oncotarget

July 27, 2021
In this 2020 paper, researchers searched for biomarkers of sacituzumab govitecan treatment efficacy in triple-negative breast cancer. continue reading »